

AACR Virtual Meeting: Clonal Hematopoiesis
August 18-19, 2021

Conference Cochairs

Ravi Majeti, Stanford University, Stanford, California

Maria E. (Ken) Figueroa, University of Miami, Miami, Florida

Wednesday, August 18, 2021

Session 1: DTA Mutations

Moderators: Maria E. (Ken) Figueroa, University of Miami, Miami, Florida and Ravi Majeti, Stanford University, Stanford, CA

Sessions 1 and 2 Introduction

Ravi Majeti

***Dnmt3a* mutations in clonal hematopoiesis**

Jennifer Trowbridge, The Jackson Laboratory, Bar Harbor, ME

TET2 mutations, inflammation-induced plasticity, and myeloid transformation

Iannis Aifantis, New York University Langone Medical Center, New York, NY

ASXL1 mutations in clonal hematopoiesis

Ravi Majeti, Stanford University, Stanford, CA

Session 2: Non-DTA Mutations

Moderators: Maria E. (Ken) Figueroa, University of Miami, Miami, Florida and Ravi Majeti, Stanford University, Stanford, CA

Mechanisms of clonal competition in the context of PPM1D mutations

Margaret A. Goodell, Baylor College of Medicine, Houston, TX

Spliceosome mutations in clonal hematopoiesis

Esther Obeng, St. Jude Children's Research Hospital, Memphis, TN

DTA vs. Non-DTA Panel Discussion

Moderators: Maria E. (Ken) Figueroa and Ravi Majeti

Panelists: Iannis Aifantis, Margaret A. Goodell, Esther Obeng, Jennifer Trowbridge

Thursday, August 19, 2021

Session 3: Clonal Hematopoiesis and Non-Blood Cancer Consequences

Moderator: Benjamin L. Ebert, Dana-Farber Cancer Institute, Boston, MA

Session Introduction

Benjamin L. Ebert

Clonal hematopoiesis and risk of cardiovascular diseases

Siddhartha Jaiswal, Stanford University, Stanford, CA

Clonal hematopoiesis and infection risk: Correlations and complications

Kelly L. Bolton, Washington University of St. Louis, St. Louis, MO

Deciphering and targeting clonal hematopoiesis

Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, NY

Session Panel Discussion

Moderator: Benjamin L. Ebert

Panelists: Siddhartha Jaiswal, Kelly L. Bolton, Ross L. Levine

Session 4: Population-Level Studies of Clonal Hematopoiesis

Moderator: Maria E. (Ken) Figueroa, University of Miami, Miami, Florida

Session Introduction

Maria E. (Ken) Figueroa

CHIP in elderly twins: Concordance, discordance, survival, and epigenetics

Kirsten Grønbaek, Rigshospitalet and BRIC, University of Copenhagen, Copenhagen, Denmark

Population studies in clonal hematopoiesis: Hematologic malignancies

Pinkal Desai, Weill Cornell Medical College, New York, NY

Clonal hematopoiesis and risk for cardiovascular disease: Insights from population-based studies

Pradeep Natarajan, Massachusetts General Hospital, Boston, MA

Session Panel Discussion

Moderator: Maria E. (Ken) Figueroa

Panelists: Pinkal Desai, Pradeep Natarajan

Panel Discussion

Clonal Hematopoiesis: How Do We Design Clinical Trials and Approve Drugs?

Moderators: Ravi Majeti, Stanford University, Stanford, CA and Maria E. (Ken) Figueroa, University of Miami, Miami, FL

Panelists

Benjamin L. Ebert, Dana-Farber Cancer Institute, Boston, MA

Kelly L. Bolton, Washington University of St. Louis, St. Louis, MO

David Steensma, Novartis, Cambridge, MA